FOLFOX和FOLFIRI方案用于大肠黏液癌辅助化疗的比较  

Comparison of FOLFOX and FOLFIRI adjuvant chemotherapy regimens in the treatment of colorectal mucinous adenocarcinoma

作　　者：刘山[1] 孟令新[1] 张可[1] 秦朝阳[1] 王刚平[1] 孟芹[1] 丁兆军[1] 

机构地区：[1]日照市人民医院肿瘤科,山东日照276826

出　　处：《现代肿瘤医学》2016年第16期2562-2564,共3页Journal of Modern Oncology

基　　金：济宁医学院面上项目(编号:JY2013KY061)

摘　　要：目的:探讨FOLFOX及FOLFIRI方案在大肠黏液腺癌术后辅助化疗中的疗效差异。方法:将40例术后病理证实为大肠黏液腺癌患者随机分为2组,实验组应用FOLFIRI方案化疗,对照组应用FOLFOX方案化疗。比较两组的无病生存时间(DFS)和不良反应,并应用Kaplan-Meier法进行生存率统计分析。结果:FOLFOX组的中位DFS为13个月,FOLFIRI组的中位DFS为18个月。FOLFIRI方案组DFS比FOLFOX方案组DFS长5个月,差异有统计学意义(P=0.038)。结论:对于大肠黏液腺癌,术后应用FOLFIRI方案化疗比FOLFOX方案可延长DFS。Objective：To evaluate the clinical effect of FOLFOX regimen and FOLFIRI regimen in the treatment of colorectal mucinous adenocarcinoma after operation. Methods：All 40 patients confirmed as mucinous adenocarcinoma by surgery and pathology were divided randomly into two groups. Twenty patients（Group FOLFOX）were treated with oxaliplatin combined with 5 - fluorouracil,while the other twenty patients（Group FOLFIRI）were treated with irinote-can combined with 5 - fluorouracil. The disease - free - survival（DFS）and side effects of the two groups was com-pared. Survival was estimated using the Kaplan - Meier method. Results：The DFS of group FOLFOX was 13 months, while the DFS of group FOLFIRI was 18 months（P = 0. 038）. Conclusion：Colorectal mucinous adenocarcinoma after operation treated with FOLFIRI regimen can prolong DFS than FOLFOX regimen.

关 键 词：黏液腺癌 大肠癌 近期疗效 辅助化疗 

分 类 号：R735.3[医药卫生—肿瘤]